MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Angiogenesis

Physiological process involving the growth of new blood vessels from pre-existing vessels; anti-angiogenesis therapies are designed at eliminating the growth of blood vessels that feed tumors.

Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications.

Oncotarget 2018 April 24 [Link] Magkouta S, Pappas A, Pateras IS, Kollintza A, Moschos C, Vazakidou ME, Karavana V, Gorgoulis VG, Kalomenidis I Abstract Malignant pleural mesothelioma is resistant to currently used treatment. Angiopoieitn-1 directly promotes mesothelioma cell growth in a Tie-2-dependent fashion. Angiopoietin/Tie-2 axis may thus be valid targets for therapeutic interventions against mesothelioma. […]

Comments Off on Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications.

Aminopeptidase N/CD13 as a Potential Therapeutic Target in Malignant Pleural Mesothelioma

The European Respiratory Journal [Epub ahead of print] [Link] Otsuki T et. al. Abstract Angiogenesis is a crucial factor in the progression of malignant pleural mesothelioma (MPM), and antiangiogenic strategies might be effective against MPM. Aminopeptidase N/CD13 (APN/CD13) promotes tumour angiogenesis and is associated with poor prognosis; however, its clinical significance in MPM remains unclear.In […]

Comments Off on Aminopeptidase N/CD13 as a Potential Therapeutic Target in Malignant Pleural Mesothelioma

Systemic Treatment of Malignant Pleural Mesothelioma

Cancer & Chemotherapy 2017 December [Link] Nakano T Abstract Malignant pleural mesothelioma(MPM)is a highly aggressive tumor with a poor prognosis and an increasing incidence worldwide. The only standard first-line chemotherapy for patients with unresectable MPM is cisplatin(CDDP)plus peme- trexed(PEM)(CDDP/PEM), with a median overall survival of about 12months and a median progression-free survival(PFS) of less than […]

Comments Off on Systemic Treatment of Malignant Pleural Mesothelioma

Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications

International Journal of Molecular Science 2018 January 13 [Link] Tolani B, Acevedo LA, Hoang NT, He B Abstract Malignant pleural mesothelioma (MPM) tumors are remarkably aggressive and most patients only survive for 5-12 months; irrespective of stage; after primary symptoms appear. Compounding matters is that MPM remains unresponsive to conventional standards of care; including radiation […]

Comments Off on Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications

Complement Protein C1q Binds to Hyaluronic Acid in the Malignant Pleural Mesothelioma Microenvironment and Promotes Tumor Growth

Frontiers in Immunology 2017 November [Link] Agostinis C et. al. Abstract C1q is the first recognition subcomponent of the complement classical pathway, which acts toward the clearance of pathogens and apoptotic cells. C1q is also known to modulate a range of functions of immune and non-immune cells, and has been shown to be involved in […]

Comments Off on Complement Protein C1q Binds to Hyaluronic Acid in the Malignant Pleural Mesothelioma Microenvironment and Promotes Tumor Growth

Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity

American Journal of Cancer Research 2017 August [Link] Tan Y, Sementino E, Chernoff J, Testa JR Abstract Clinical management of malignant mesothelioma (MM) is very challenging due to marked resistance of this tumor to chemotherapy. Various mechanisms lead to a less than ideal drug concentration inside of MM cells, diminishing cytotoxicity. Consequently, single cytotoxic drugs […]

Comments Off on Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity

Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma

Human Pathology 2017 August 12 [Epub ahead of print] [Link] Inaguma S, Lasota J, Wang Z, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Ikeda H, Schrump DS, Hassan R, Miettinen M Abstract Diffuse malignant mesothelioma of the pleura is a highly aggressive tumor typically associated with short survival. […]

Comments Off on Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma

A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group

Lung Cancer (Netherlands) 2017 February [Epub 2016 December 15] [Link] Laurie SA, Hao D, Leighl NB, Goffin J, Khomani A, Gupta A, Addison CL, Bane A, Seely J, Filion ML, Pond GR, Levine MN Abstract OBJECTIVES: Following failure of a platinum-antifolate combination regimen, there is no standard therapy for advanced malignant pleural mesothelioma (MPM). The […]

Comments Off on A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group

A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207

Journal of Thoracic Oncology 2016 November [Epub 2016 July 20] [Link] Wheatley-Price P, Chu Q, Bonomi M, Seely J, Gupta A, Goss G, Hilton J, Feld R, Lee CW, Goffin JR, Maksymiuk A, Murray N, Hagerman L, Bradbury PA Abstract There is no approved second-line systemic therapy option for malignant pleural mesothelioma (MPM), but targeting […]

Comments Off on A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207

Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma

Expert Review of Anticancer Therapy 2016 October 4 [Epub ahead of print] [Link] Chia PL, Russell P, Scott AM, John T Abstract INTRODUCTION: Malignant mesothelioma (MM) is an aggressive malignancy of the pleura and other serosal membranes originating from mesothelial cells that, despite decades of research, continues to have limited therapeutic options and is associated […]

Comments Off on Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma